01781nas a2200373   4500000000100000008004100001260001300042653001500055653001000070653001000080653002100090653003000111653001100141653002200152653001100174653001100185653002300196653001200219653002400231653002500255653000900280653001600289653001500305100001700320700001900337700001200356700001500368245012100383856004100504300001100545490000700556520083000563022001401393       1991                            d  c1991 Jun10aAdolescent10aAdult10aChild10aChild, Preschool10aDrug Therapy, Combination10aFemale10aFollow-Up Studies10aHumans10aInfant10aLeprostatic Agents10aleprosy10aLeprosy, Borderline10aLeprosy, Tuberculoid10aMale10aMiddle Aged10aRecurrence1 aBoerrigter G1 aPonnighaus J M1 aFine PE1 aWilson R J00aFour-year follow-up results of a WHO-recommended multiple-drug regimen in paucibacillary leprosy patients in Malawi.  uhttp://ila.ilsl.br/pdfs/v59n2a06.pdf  a255-610 v593 a<p>An evaluation of a World Health Organization-recommended multidrug therapy (WHO/MDT) in 499 paucibacillary leprosy patients is described. Patients were followed for 48 months after completion of treatment. Overall relapse rates after treatment were found to be 6.5 per 1000 person years (95% confidence interval 3.4-11.4). There were 12 relapses. A relative lack of cell-mediated immunity, as suggested by number of lesions, clinical classification and lepromin test results, and poor compliance with the dapsone component of WHO/MDT, appeared to be associated with a marginally increased risk of relapse. Severe type 1 reactions after completion of treatment occurred in 17 (3.5%) patients, 15/17 during the first 12 months of follow-up. Overall, 12 (2.5%) patients developed new disabilities during or after WHO/MDT.</p>  a0148-916X